TY - JOUR
T1 - The public health control of scabies
T2 - priorities for research and action
AU - Engelman, Daniel
AU - Cantey, Paul T.
AU - Marks, Michael
AU - Solomon, Anthony W.
AU - Chang, Aileen Y.
AU - Chosidow, Olivier
AU - Enbiale, Wendemagegn
AU - Engels, Dirk
AU - Hay, Roderick J.
AU - Hendrickx, D.
AU - Hotez, Peter J.
AU - Kaldor, John M.
AU - Kama, Mike
AU - Mackenzie, Charles D.
AU - McCarthy, James S.
AU - Martin, Diana L.
AU - Mengistu, Birhan
AU - Maurer, Toby
AU - Negussu, Nebiyu
AU - Romani, L.
AU - Sokana, Oliver
AU - Whitfeld, Margot J.
AU - Fuller, L. Claire
AU - Steer, Andrew C.
PY - 2019/7/6
Y1 - 2019/7/6
N2 - Scabies is a parasitic disease of the skin that disproportionately affects disadvantaged populations. The disease causes considerable morbidity and leads to severe bacterial infection and immune-mediated disease. Scientific advances from the past 5 years suggest that scabies is amenable to population-level control, particularly through mass drug administration. In recognition of these issues, WHO added scabies to the list of neglected tropical diseases in 2017. To develop a global control programme, key operational research questions must now be addressed. Standardised approaches to diagnosis and methods for mapping are required to further understand the burden of disease. The safety of treatments for young children, including with ivermectin and moxidectin, should be investigated. Studies are needed to inform optimum implementation of mass treatment, including the threshold for intervention, target, dosing, and frequency. Frameworks for surveillance, monitoring, and evaluation of control strategies are also necessary.
AB - Scabies is a parasitic disease of the skin that disproportionately affects disadvantaged populations. The disease causes considerable morbidity and leads to severe bacterial infection and immune-mediated disease. Scientific advances from the past 5 years suggest that scabies is amenable to population-level control, particularly through mass drug administration. In recognition of these issues, WHO added scabies to the list of neglected tropical diseases in 2017. To develop a global control programme, key operational research questions must now be addressed. Standardised approaches to diagnosis and methods for mapping are required to further understand the burden of disease. The safety of treatments for young children, including with ivermectin and moxidectin, should be investigated. Studies are needed to inform optimum implementation of mass treatment, including the threshold for intervention, target, dosing, and frequency. Frameworks for surveillance, monitoring, and evaluation of control strategies are also necessary.
UR - http://www.scopus.com/inward/record.url?scp=85068253326&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(19)31136-5
DO - 10.1016/S0140-6736(19)31136-5
M3 - Review article
C2 - 31178154
AN - SCOPUS:85068253326
SN - 0140-6736
VL - 394
SP - 81
EP - 92
JO - The Lancet
JF - The Lancet
IS - 10192
ER -
